Langerhans cell histiocytosis-Analysis of new biomarkers using NGS (small RNA)

Research Project

Project/Area Number	20K07393
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 49020:Human pathology-related
Research Institution	Kochi University
Principal Investigator	Murakami Ichiro 高知大学, 教育研究部医療学系連携医学部門, 教授 (80548701)
Project Period (FY)	2020-04-01 – 2023-03-31
Project Status	Completed (Fiscal Year 2022)
Budget Amount *help	¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000) Fiscal Year 2022: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000) Fiscal Year 2021: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000) Fiscal Year 2020: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Keywords	Histiocytosis / RNA-Seq / mRNA / ncRNA / ランゲルハンス細胞組織球症 / RNA解析 / ncRNA解析 / miRNA解析
Outline of Research at the Start	LCHは腫瘍性疾患なのか反応性疾患なのか未確定である（研究課題の核心をなす学術的「問い」）。我々は、LCHは腫瘍性疾患の性格を背景にした反応性疾患である可能性（Hum Pathol, 2014））を得、LCH患者血清を用いた質量分析器による解析（平成２３年度基盤研究（C）及び平成２６年度基盤研究（C））、LCH患者血清を用いたRNA-Seq (対象にsmall RNAを含まないHiSeq) （平成２９年度基盤研究（C））と継続してきた。本研究に於いては、LCH患者血清を用いたRNA-Seq (small RNAを対象としたNovaSeq) 解析を進める事を検討している。
Outline of Final Research Achievements	The cause of Langerhans cell histiocytosis (LCH) is uncertain, whether it is neoplastic or reactive disease (KAKENHI 20K07393). Various involvements such as viral infections, congenital anomalies, etc. have been investigated (Hum Pathol, 2014). We obtained data suggesting that LCH may be a reactive disease with neoplastic characteristics, and analyzed LCH patient sera by mass spectrometry, followed by RNA-Seq using LCH patient sera. LCH is now recognized as an inflammatory myeloid neoplasm.
Academic Significance and Societal Importance of the Research Achievements	Based on these data, it is suggested that therapeutic strategies should target not only neoplastic disease but also reactive disease.